Status:
UNKNOWN
Inflammation, NK Cells, Antisense Protein and Exosomes, and Correlation With Immune Response During HIV Infection
Lead Sponsor:
University Hospital, Montpellier
Conditions:
HIV Infections
Eligibility:
All Genders
45+ years
Phase:
NA
Brief Summary
More than 90% of HIV-infected patients on antiretroviral therapy have an undetectable viral load. However, approximately 15% of these individuals do not sufficiently restore their TCD4 lymphocytes and...
Detailed Description
The main objective of the project is to characterize the presence of ex vivo NK cell perturbations in patients living with HIV (PLHIV) with immunovirological discordance, in relation to ASP expression...
Eligibility Criteria
Inclusion
- Patiens living with HIV over 45 years old
- At least 2 measurements of CD4+ T-cell and HIV viral load in the last 2 years
- HIV viral load \< 50 copies/ml in the past 2 years
- For the immune non-responder patients : CD4+ T-cell count \< 350 cells/mm3 on the last two tests
- For the immune responder patients: CD4+ T-cell count \> 500 cells/mm3 on the last two tests
Exclusion
- No antiretroviral treatment
- Immunosuppressive treatment
- History of cancer less than 5 years
- Pregnancy
- Breastfeeding mother
- Adult protected by law or patient under guardianship or curatorship
- Failure to obtain written informed consent after a reflection period
- Not be affiliated to a French social security system or a beneficiary of such a system
Key Trial Info
Start Date :
April 22 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2024
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT05243381
Start Date
April 22 2022
End Date
April 1 2024
Last Update
September 7 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
La Colombiere Hospital
Montpellier, Herault, France, 34295